Ramucirumab + Placebo + Oxaliplatin + Leucovorin + 5-Fluorouracil
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Cancer
Conditions
Stomach Cancer, Esophageal Cancer
Trial Timeline
Apr 1, 2011 → May 1, 2014
NCT ID
NCT01246960About Ramucirumab + Placebo + Oxaliplatin + Leucovorin + 5-Fluorouracil
Ramucirumab + Placebo + Oxaliplatin + Leucovorin + 5-Fluorouracil is a phase 2 stage product being developed by Eli Lilly for Stomach Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01246960. Target conditions include Stomach Cancer, Esophageal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01246960 | Phase 2 | Completed |
Competing Products
20 competing products in Stomach Cancer